Wednesday, July 8, 2026

Drug profile · INN

alvimopan

alvimopan (ALVIMOPAN) is a mu opioid receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — alvimopan
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.89

Quick answer

alvimopan (ALVIMOPAN) is a mu opioid receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN alvimopan
Brand ALVIMOPAN
Mechanism Mu opioid receptor antagonist
Target Mu-type opioid receptor
Route ORAL
Formulation CAPSULE

Mechanism of action

Mu opioid receptor antagonist

Primary target: Mu-type opioid receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. alvimopan Phase 2 · Merck KGaA, Darmstadt · Constipation

Related & competitor drugs

  1. loperamide hydrochloride Mu opioid receptor agonist
  2. methadone hydrochloride Mu opioid receptor agonist
  3. morphine sulfate Mu opioid receptor agonist
  4. oxycodone Mu opioid receptor agonist
  5. oxycodone hydrochloride Mu opioid receptor agonist
  6. propoxyphene hydrochloride Mu opioid receptor agonist

Frequently asked questions

What is alvimopan?

alvimopan (ALVIMOPAN) is a mu opioid receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for alvimopan?

ALVIMOPAN is a marketed brand name for alvimopan. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of alvimopan?

alvimopan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.